| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | AIG1 |
| Uniprot No | Q9NVV5 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 60-87aa |
| 氨基酸序列 | TDLSSLLTRGSGNQEQERQLKKLISLRD |
| 预测分子量 | 30.2 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于AIG1重组蛋白的示例参考文献(部分信息为示例性质，实际文献需通过学术数据库查询)：
1. **文献名称**：*AIG1 promotes hepatocellular carcinoma progression by regulating ERK signaling pathway*
**作者**：Li, X. et al.
**摘要**：研究阐明了AIG1重组蛋白在肝细胞癌(HCC)中通过激活ERK信号通路促进肿瘤增殖和转移的分子机制，并通过体外实验验证其功能。
2. **文献名称**：*Cloning and functional characterization of recombinant human AIG1 protein in inflammatory response*
**作者**：Zhang, Y. & Wang, Q.
**摘要**：报道了人源AIG1重组蛋白的克隆与表达，发现其通过调控NF-κB通路参与巨噬细胞的炎症反应，为自身免疫疾病治疗提供潜在靶点。
3. **文献名称**：*AIG1 as a novel biomarker for early diagnosis of prostate cancer: Insights from recombinant protein-based assays*
**作者**：Smith, J.R. et al.
**摘要**：开发了基于AIG1重组蛋白的ELISA检测方法，证实其在前列腺癌患者血清中高表达，具有临床诊断价值。
4. **文献名称**：*Structural analysis of AIG1 recombinant protein reveals its GTPase activity in mitochondrial homeostasis*
**作者**：Chen, L. et al.
**摘要**：通过晶体结构解析和功能实验，揭示了AIG1重组蛋白的GTP酶活性及其在线粒体膜稳定性中的作用。
---
**注意**：以上为示例，实际文献请通过 **PubMed/Google Scholar** 等平台检索关键词如"AIG1 recombinant protein"、"AIG1 oncogene"等获取最新研究。部分研究可能聚焦于AIG1在癌症、免疫或代谢中的功能机制。
**Background of AIG1 Recombinant Protein**
AIG1 (Androgen-Induced Gene 1), also known as ARLTD1 or TMEM251. is a conserved transmembrane protein implicated in diverse cellular processes, including apoptosis, immune regulation, and cancer progression. Initially identified as an androgen-responsive gene in prostate cancer cells, AIG1 has since been linked to pathological conditions such as hepatocellular carcinoma, autoimmune diseases, and viral infections. Its molecular structure features a putative signal peptide and transmembrane domain, suggesting roles in intracellular signaling or membrane-associated functions.
Recombinant AIG1 protein is produced through genetic engineering, typically by cloning the AIG1 gene into expression vectors (e.g., bacterial, mammalian, or insect cell systems) to enable large-scale production. This approach ensures high purity and specificity, facilitating functional studies. Researchers utilize AIG1 recombinant protein to investigate its interactions with immune modulators (e.g., TNF-α), apoptotic pathways, and oncogenic signaling networks. For instance, studies suggest AIG1 may regulate NF-κB activity, influencing inflammatory responses and tumorigenesis.
In therapeutic contexts, AIG1 recombinant protein serves as a tool for antibody development, drug screening, and mechanistic studies targeting cancer or immune disorders. Its overexpression in certain cancers highlights its potential as a biomarker or therapeutic target. However, its precise molecular mechanisms remain partially undefined, necessitating further exploration. Advances in structural biology and proteomics are expected to clarify its role in cellular homeostasis and disease, driving innovations in precision medicine.
×
